Francis deSouza

Illumina Introduces Multiple Breakthrough Sequencing Innovations at Inaugural Genomics Forum

Retrieved on: 
Thursday, September 29, 2022
YouTube, Double-barrelled name, Francis deSouza, Health, RUO, Time, Agriculture, Gaps, Twitter, Illumina, Inc., FDA, LinkedIn, Compliance, Review, IVD, U.S. Securities and Exchange Commission, Ownership, Reproductive health, Technology, Instagram, Dry ice, NASDAQ, SAN, Genomics, Research, DNA, Security (finance), SBS, Infinity, Form 10-K, Genome, Patent, Disease, Fine chemical, Antibiotics, Illumina, Chemistry, Facebook

SAN DIEGO, Sept. 29, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced multiple breakthrough sequencing innovations at its inaugural Illumina Genomics Forum:

Key Points: 
  • Illumina Complete Long-Reads, formerly known as Infinity, will accelerate access to the remaining 5% of genic regions with a scalable, high-throughput, low DNA-input long read technology.
  • Further, the technology provides a complete and accurate representation of the genome at the single molecule level without needing a new platform.
  • These announcements came on the second day of the inaugural Illumina Genomics Forum, which runs through October 1.For more information, please visit illuminagenomicsforum.com .
  • Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets.

llumina Announces Opportunity to View Live Webcast of Illumina Genomics Forum Innovation Roadmap Session Followed by Investor Conference Call

Retrieved on: 
Thursday, September 8, 2022
Francis deSouza, Interest, Double-barrelled name, Research, Agriculture, SAN, Reproductive health, NASDAQ, YouTube, Pacific Time Zone, Interim, Corporate development, LinkedIn, DNA, Illumina, Inc., Genome, Instagram, Conference, Twitter, Health, Public relations, Illumina, Eastern Time Zone, Facebook

SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that investors, analysts, and other interested parties may view a live webcast of the Innovation Roadmap session of the Illumina Genomics Forum, which will be hosted by Francis deSouza, Chief Executive Officer, and Alex Aravanis, Chief Technology Officer.

Key Points: 
  • SAN DIEGO, Sept. 8, 2022 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that investors, analysts, and other interested parties may view a live webcast of the Innovation Roadmap session of the Illumina Genomics Forum, which will be hosted by Francis deSouza, Chief Executive Officer, and Alex Aravanis, Chief Technology Officer.
  • The session will be held from 9:00-10:00am Pacific Time (12:00-1:00pm Eastern Time), Thursday, Sept. 29, 2022.
  • Interested parties may access the live webcast of the Innovation Roadmap session of the Illumina Genomics Forum through the Investor Info section of Illumina's website at investor.illumina.com .
  • Individuals may access the live investor conference call with Illumina management through the same page or, alternatively, by dialing 866.409.1555 or +1.313.209.4906 outside North America, both with Conference ID 7572314.

Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease

Retrieved on: 
Tuesday, November 16, 2021
National Institutes of Health, Francis deSouza, Genetics, Medicine, Culture, Health, SAN, Illumina, Inc., Organization, Security (finance), NASDAQ, WGS, Disease, Doctor of Philosophy, Technology, Double-barrelled name, Human Genome Project, National, Income, Alliance, Carson City IHOP shooting, Face, Instagram, Geography, Research, Program, Human, YouTube, Genetic Alliance, Twitter, Foundation, Genome, U.S. Securities and Exchange Commission, Form 10-K, Genetic disorder, LinkedIn, Laboratory, Scientific method, Lists of diseases, Diagnosis, Reproductive health, Review, Time, DNA, Genetic Alliance UK, Patient, Agriculture, Pharmaceutical industry, Vaccine

"Since our inception in 1986, Genetic Alliance's mission has been to realize a world in which those affected by genetic disease are diagnosed and offered interventions to alleviate their suffering," said Genetic Alliance CEO, Sharon Terry.

Key Points: 
  • "Since our inception in 1986, Genetic Alliance's mission has been to realize a world in which those affected by genetic disease are diagnosed and offered interventions to alleviate their suffering," said Genetic Alliance CEO, Sharon Terry.
  • Genetic disease affects over 300 million individuals worldwide, the vast majority of whom are children.
  • I applaud Genetic Alliance for launching this important initiative to improve access to this life-changing technology.
  • "iHope Genetic Health will change the trajectory of genomic medicine worldwide, helping patients who may have otherwise been invisible.

Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development

Retrieved on: 
Monday, May 17, 2021
Oncology, Health, Genetics, Other Science, Science, Biotechnology, Microarrays, Businesspeople, Technology, DNA sequencing, Illumina, Inc., Francis deSouza, Lumi, Science and technology, Chief technology officer

b'Illumina, Inc. (NASDAQ: ILMN) today announced that it is appointing Susan Tousi as Chief Commercial Officer (CCO), and Dr. Alex Aravanis as Chief Technology Officer (CTO), Head of Research and Product Development.\n\xe2\x80\x9cWe\xe2\x80\x99re fortunate to have Susan and Alex, two of the strongest leaders in the genomics industry, take on these large, important roles,\xe2\x80\x9d said Francis deSouza, Chief Executive Officer of Illumina.

Key Points: 
  • b'Illumina, Inc. (NASDAQ: ILMN) today announced that it is appointing Susan Tousi as Chief Commercial Officer (CCO), and Dr. Alex Aravanis as Chief Technology Officer (CTO), Head of Research and Product Development.\n\xe2\x80\x9cWe\xe2\x80\x99re fortunate to have Susan and Alex, two of the strongest leaders in the genomics industry, take on these large, important roles,\xe2\x80\x9d said Francis deSouza, Chief Executive Officer of Illumina.
  • She has received numerous business, technology, and leadership awards, and was elected to the National Academy of Engineers in 2018.
  • \xe2\x80\x9cI look forward to strengthening relationships between Illumina\xe2\x80\x99s research and development teams and our customers, boosting our offerings and benefiting all.
  • Alex returned to Illumina in June 2020 as CTO, leading the company\xe2\x80\x99s research and technology development and the innovation engine for next-generation sequencing platforms and applications.

Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Retrieved on: 
Tuesday, April 20, 2021
Research, Technology, Medical devices, Genetics, Other Technology, General Health, Health, Science, Oncology, Other Science, Microarrays, DNA sequencing, Technology, Businesspeople, Illumina, Inc., Grail, Biology, Francis deSouza, Lumi

b'Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with the European Commission\xe2\x80\x99s Directorate-General for Competition\xe2\x80\x99s decision to review Illumina\xe2\x80\x99s acquisition of GRAIL, a company founded to accelerate early screening of cancer.

Key Points: 
  • b'Illumina, Inc. (NASDAQ: ILMN), today announced that it disagrees with the European Commission\xe2\x80\x99s Directorate-General for Competition\xe2\x80\x99s decision to review Illumina\xe2\x80\x99s acquisition of GRAIL, a company founded to accelerate early screening of cancer.
  • Illumina will continue to work with the Directorate-General to bring the investigation to conclusion.
  • Illumina remains committed to the transaction, the impact of which would accelerate the adoption of a multi-cancer early detection blood test.\n\xe2\x80\x9cReuniting GRAIL and Illumina will allow us to bring GRAIL\xe2\x80\x99s breakthrough early detection multi-cancer test to patients across the world faster and consequently save lives,\xe2\x80\x9d said Francis deSouza, Chief Executive Officer of Illumina.
  • Together with GRAIL, Illumina looks forward to changing the course of cancer detection and treatment.\nIllumina is improving human health by unlocking the power of the genome.

Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021

Retrieved on: 
Monday, April 5, 2021
Biotechnology, Technology, Health, Pharmaceutical, Oncology, Other Science, Other Technology, Medical devices, Research, Genetics, Science, Microarrays, Technology, DNA sequencing, Illumina, Inc., Businesspeople, Biology, Francis deSouza, Lumi

Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance.

Key Points: 
  • Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance.
  • Subject to quarter-end closing adjustments, Illumina expects to report first quarter 2021 revenue of approximately $1,085 million, compared to $859 million in the first quarter of 2020.
  • For fiscal year 2021, Illumina now expects year-over-year revenue growth in the range of 25%-28% compared to fiscal year 2020.
  • This is reflected in our outstanding preliminary first quarter revenue and, as a result, we are raising our 2021 revenue guidance, said Francis deSouza, President and CEO.

Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test

Retrieved on: 
Tuesday, March 30, 2021
Oncology, Health, Genetics, Other Science, Research, Science, Biotechnology, Microarrays, Businesspeople, Technology, DNA sequencing, Illumina, Inc., Grail, Francis deSouza, Biology, Lumi, Illumina, Cancer screening

Illumina will pursue its right to proceed with the transaction, the impact of which would accelerate the adoption of a breakthrough multi-cancer early detection blood test.

Key Points: 
  • Illumina will pursue its right to proceed with the transaction, the impact of which would accelerate the adoption of a breakthrough multi-cancer early detection blood test.
  • Improving early cancer detection is the most promising approach to bending the cancer mortality curve, said Francis deSouza, Chief Executive Officer of Illumina.
  • Illumina strongly believes that acquiring GRAIL is in the best interest of patients, is procompetitive, and benefits the multi-cancer early detection field as a whole.
  • Illumina intends to pursue all legal options in order to complete the acquisition and deliver the strategic benefits to its stakeholders.

Illumina Welcomes Kathryne Reeves as Chief Marketing Officer

Retrieved on: 
Tuesday, August 25, 2020
Marketing, Health, Communications, Genetics, Research, Science, Biotechnology, Business, Articles, Francis deSouza, Illumina, Inc., Marketing, Chief marketing officer

Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020.

Key Points: 
  • Illumina (NASDAQ: ILMN) announced today that Kathryne Reeves will join the company as Chief Marketing Officer on September 28, 2020.
  • Reeves brings more than 25 years of marketing and general management experience in roles across the healthcare, technology, and consumer products industries.
  • Reeves will report to Chief Executive Officer, Francis deSouza.
  • Kathryne has a strong track record of successfully building brands, bringing innovation to markets, deepening customer engagement, and growing revenue across a multitude of industries, said Francis deSouza, Illuminas Chief Executive Officer.

Illumina Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development

Retrieved on: 
Monday, May 4, 2020
Health, Genetics, Microarrays, Businesspeople, DNA sequencing, Illumina, Inc., Biology, Technology, Francis deSouza, Mostafa Ronaghi, Lumi, Illumina

Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer.

Key Points: 
  • Illumina (NASDAQ: ILMN) today announced the appointment of Alex Aravanis as Chief Technology Officer.
  • Dr. Aravanis will join Illumina in early June and will report to Chief Executive Officer, Francis deSouza.
  • Mostafa Ronaghi, who served as Illuminas Chief Technology Officer, is taking on a new role as Senior Vice President of Entrepreneurial Development, responsible for supporting and catalyzing the expanding genomics entrepreneurial ecosystem.
  • We are thrilled to welcome Alex back to Illumina, now as our Chief Technology Officer, to ensure that Illumina will continue to deliver cutting edge technology to support the ever-broader adoption and impact of genomics, said Francis deSouza, Illuminas Chief Executive Officer.

Dr. Scott Gottlieb, former US FDA Commissioner, joins Illumina’s Board of Directors

Retrieved on: 
Thursday, February 6, 2020
Oncology, Medical devices, Health, Genetics, Pharmaceutical, Biotechnology, Businesspeople, Health, United States Department of Health and Human Services, United States Public Health Service, Francis deSouza, Food and Drug Administration, Scott Gottlieb, Criticism of the Food and Drug Administration

has joined the companys Board of Directors, effective February 4, 2020.

Key Points: 
  • has joined the companys Board of Directors, effective February 4, 2020.
  • From 2017 to 2019, he served as the 23rd commissioner of the Food and Drug Administration (FDA).
  • Prior to joining the FDA as commissioner, he was a clinical assistant professor at New York University School of Medicine.
  • I am excited to welcome Scott to Illuminas Board of Directors, said Francis deSouza, Illuminas Chief Executive Officer.